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Summary
Objective: A subgroup of patients with pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (MED) have been found to harbor
mutations within the cartilage oligomeric matrix protein (COMP) gene. These two diseases are autosomal dominant disorders that are
characterized by an early onset of osteoarthritis (OA). The COMP gene is expressed primarily in chondrocytes in articular cartilage as well
as in tendon and ligament. Therefore, control over tissue specific COMP expression may be an important aspect in cartilage biology. To begin
an analysis of the regulation of COMP expression, we have cloned, sequenced and characterized the entire genomic clone for mouse COMP
that includes the COMP promoter.
Methods and Results: The COMP coding region spans 19 exons over approximately 8.4 kb of DNA. The arrangement and size of the exons
have a remarkable similarity to those of the human COMP genomic sequence, indicating a significant degree of genomic conservation.
Analysis of a 453 basepair region of the putative COMP promoter reveals two strong transcriptional repressor elements located between
position −356 and −304 and between −251 and −180, relative to the start site for transcription. These repressor elements down-regulate
transcription from the promoter in a broad spectrum of cell lines. Removal of the repressor DNA sequence from the COMP promoter leads
to significant enhancement in transcriptional activity, indicating that this region acts in a dominant manner to transcriptional activators located
more proximal to the start site of transcription. This region also represses transcription when linked to a heterologous promoter.
Conclusions: This repressor region probably down-regulates transcription from the COMP promoter in vivo. It may help to repress
transcription of COMP in non-cartilaginous tissues and/or may aid in the expression of COMP to the appropriate level in tissues such as
cartilage, tendon and ligament. © 2002 Elsevier Science Ltd on behalf of OsteoArthritis Research Society International.
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Cartilage oligomeric matrix protein (COMP) is a 524 kD
oligomeric glycoprotein1,2. It is a member of the
thrombospondin gene family2,3 and the mature protein is a
pentamer of identical subunits. These subunits interact at
their N-terminus through disulfide linkages, forming a
bouquet-like structure1,4,5. COMP contains four epidermal
growth factor-like repeats (type 2 repeats), at the amino
terminal portion of the protein and eight calcium binding
repeats (type 3 repeats) located in the central region of the
protein3. The type 2 and type 3 repeats are contained in the
thrombospondins3. The pentamer is formed from an alpha-
helical coiled-coil structure at the amino terminus3,4,6. The
central region of COMP is similar to transmembrane ion
channels in that it is cylindrical and relatively hydrophobic6.
This is consistent with the recent finding that a number of
hydrophobic compounds, such as retinoic acid, retinol and
vitamin D3, bind to COMP in this central region7. It has
been proposed that COMP may serve as a storage and
delivery function for these important biological mediators7.638COMP was originally identified as a component of
cartilage and has been found to be highly expressed in
both developing and mature cartilage as well as in tendon
and ligament1,8–10. In adult cartilage, COMP has been
shown to be located primarily in the interterritorial matrix9.
Yet, during human fetal development, COMP was most
pronounced in the territorial matrix around the chondro-
cytes of the growth plate9. This pattern was also evident
during mouse development10. Since COMP is localized to
the territorial matrix of the chondrocytes it has been pro-
posed that it may interact directly with cells. But whether
COMP plays a direct role in the control of chondrocyte
proliferation and differentiation is not known at this time.
While the function of COMP in cartilage is not yet known,
mutations in the COMP gene have been identified that are
responsible for at least two forms of heritable osteoarthritis
(OA), multiple epiphysial dysplasia (MED or EDM1)
and pseudoachondroplasia (PSACH)11,12. Since the initial
identification of COMP as the causative agent in MED and
PSACH, a large number of mutations have been identified
in the COMP gene in these patients13–19. These findings
have led to the postulate that certain features of
heritable as well as sporadic OA may have roots in the
non-collagenous components of cartilage such as COMP.
While it is clear that COMP plays an important role in
cartilage function, its normal role in this tissue is not yet
known. Further understanding of the normal function of
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ISOLATION OF MURINE GENOMIC COMP
The genomic clone for mouse COMP was isolated from
a PAC (phage artificial chromosome) library. This library
was generated from a mouse cell line derived from the
129/SvJ strain of mice. A PCR directed approach was used
to first isolate the PAC clone, using primers designed from
the published rat sequence:
sense: ACGGTGATGGAATGTGACGC
antisense: CGTCGGTCGAGTGCGAGCCGTTGC
The clone spanned approximately 21.1 kb of DNA
sequence. The clone was digested with EcoR1 into two
fragments (one approximately 8.1 kb, termed E27, and the
other 13 kb, termed E55). Both strands of the E27 fragmentwere completely sequenced using primers generated from
the mouse COMP sequence. The 5′ end of the E55
fragment was also completely sequenced. The genomic
sequence was compared to the recently published mouse
cDNA sequence20 to identify the exons. The MacVector
Align® software was used in the alignments of the cDNA
and genomic sequence for the identification of the
exons and introns. All DNA sequencing was performed at
the Kimmel Cancer Centers DNA sequencing facility at
Thomas Jefferson University.Fig. 1. Genomic structure of murine COMP and its alignment to the human COMP genomic sequence. (a) The murine COMP genomic clone
was isolated from a Phage Artificial Chromosome (PAC) library. Two continuous clones (E27 and E57) were isolated and both strands from
each clone were completely sequenced. Comparison of the sequences of the genomic clones to the full-length mouse COMP cDNA yielded
the positions and sizes of the exons and introns. The size in bp of each exon and intron is shown. The 19 exons span 8.4 kb of DNA
sequence. (b) The mouse and human genomic clones are aligned. The alignments of the exons and introns between the mouse and human
sequences are shown. The exons are arranged in four groups, based on the similarity in structure between the mouse and human genes.
The exons in the human gene containing the mutations in multiple epiphseal dysplasia (MED) and pseudoachondroplasia (PSACH) are
indicated.PROMOTER CONSTRUCTIONS
All COMP promoter–reporter deletion constructs were
generated by PCR techniques with gene specific primers.
All deletion constructs were cloned into the pGL3-Basic
luciferase vector (Promega). pGL3 contains only the luci-
ferase reporter gene. All the deletion constructs were
cloned immediately adjacent and 5′ to the luciferase gene.
All 5′ deletion constructs were fixed at the 3′ end at position
+14 relative to the start site for transcription. Additionally, a
region of the COMP promoter, spanning residues −453 to
−180, was cloned into the pGL3-Promoter Vector
(Promega) and into the pGL3-Control Vector (Promega).
The pGL3-Promoter Vector contains the SV40 early pro-
moter cloned 5′ to the luciferase gene. The pGL3-Control
Vector contains the SV40 early promoter cloned 5′ to the
luciferase gene as well as the SV40 enhancer cloned 3′COMP in cartilage will depend on an in-depth analysis of
the COMP gene. Towards this goal, we have isolated,
completely sequenced and characterized the genomic
clone for mouse COMP. An alignment of the sequences,
including the 5′ flanking end, displays a high degree of
similarity in genomic structure between the mouse and
human COMP genes. Analysis of the more proximal region
of the murine COMP promoter reveals the presence of a
strong transcriptional repressor within this region.
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cloned immediately 5′ to the SV40 early promoter in the
‘pGL3-Promoter Vector’ and in the ‘pGL3-Control Vector’.CELL CULTURE AND TRANSFECTIONS
C3H10T1/2 fibroblasts (a pluripotential mesenchymal
cell line from day 10 1/2 mouse embryos), rat chondro-
sarcoma cells (RCS), Saos2 cells (human osteosarcoma
cells), U2OS cells (human osteogenic sarcoma), Phoenix
cells (a derivative of 293 cells which are adenovirus trans-
formed human embryonic kidney cells) and COS cells
(SV40 virus transformed African monkey kidney cells) were
maintained in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal calf serum. All transfection exper-
iments were initiated on 50% confluent monolayer cultures.
Plasmids (a total of 30 micrograms) were transfected by the
calcium phosphate procedure. The cells were glycerol
shocked 5–6 h after DNA addition. Extracts were generated
by multiple freeze thaw cycles approximately 24 h after the
glycerol shock. Equal amounts of protein from the soluble
extracts were assayed either for luciferase activity or for
-galactosidase activity. All transfections were performed at
least three times. A plasmid containing the Rous sarcoma
virus long terminal repeat (RSV-LTR) driving expression of
the -galactosidase gene (RSV-gal) was included in all
transfections so that the luciferase activity could be normal-
ized for differences in transfection efficiency.
The Sox 9 expression plasmid, FLAG epitope tagged
and cloned into pcDNA3 was kindly provided by Dr Benoit
de Crumbrugghe (Baylor College of Medicine) and wasused in cotransfection studies with the COMP promoter
constructs outlined below21. pcDNA3-Sox9 is a eukaryotic
expression vector containing the immediate early promoter
of cytomegalovirus immediately 5′ to the Sox9 gene.
pcDNA3 will express Sox9 to high levels across a large
number of cell lines.ResultsFig. 2. Alignment of the 5′ flanking sequence of the murine and human COMP genes. The sequence of the 5′ flanking 483 nucleotides of the
mouse and human genomic clones are aligned as shown (the numbering is relative to the transcription start site). The positions of the TATA
box and the translation initiation site are indicated. The nucleotide sequences that are homologous between the two sequences are
underlined. The start site of transcription is indicated by the horizontal arrow and the ribosome binding site is located just adjacent to the ATG.
The positions of the consensus binding sites for known transcription factors are shown in bold. Asterisks indicate positions of identity
between the mouse and human sequences that do not correspond to the binding sites of any known transcription factors.ISOLATION OF THE MURINE COMP GENOMIC SEQUENCE
Using the published sequence for rat COMP, sense
and antisense primers were generated and used in PCR
reactions with a mouse Phage Artificial Chromosome (PAC)
library. PCR techniques were used to amplify and isolate a
COMP genomic clone. This clone was digested with EcoR1
and two separate pieces were generated, termed E27 and
E55, which were separately subcloned. The majority of the
COMP gene sequence was contained within the E27 clone,
with only the last three exons in the E55 clone. The E27
clone was sequenced completely (both strands) and the
nucleotide sequence was compared with the recently pub-
lished complete cDNA sequence for the mouse COMP
gene20. The 5′-most 900 nucleotides of the E55 clone were
also sequenced. This information enabled us to identify the
exons and introns within the COMP gene. As shown in
Fig. 1(a), the genomic clone contains 19 exons spanning
over 8.4 kb of genomic DNA. The positions of the E27 and
E55 within the genomic sequence are also indicated (only
the very 5′ end of the E55 fragment is shown). The exons
vary in size from 47 to 182 bp, while the introns vary in size
Osteoarthritis and Cartilage Vol. 10, No. 8 641Fig. 3. Deletion analysis of the COMP promoter reveals the presence of multiple repressor regions. (a) Schematic of promoter-luciferase
constructs. The 3′ end of each construct was fixed at position +14, relative to the start site of transcription. The position of the 5′ ends of each
construct are shown, each position is relative to the start site of transcription. Thirty g of each promoter construct were individually
transfected into either C3H10T1/2 murine mesencymal fibroblasts (b) or rat chondrosarcoma cells (RCS) (C). At 48 h post-transfection the
cells were harvested, extracts generated and assayed for luciferase activity. Additionally, an RSV-beta galactosidase plasmid was
co-transfected along with each promoter construct to normalize for differences in transfection efficiency. Shown in (b) and (c) are the resulting
levels of promoter activity relative to the −453 construct, which was arbitrarily set at 1. Each experiment was performed multiple times and
the mean values (±S.D.) are shown.
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947 bp are spaced somewhat evenly across the gene. The
sequence in Fig. 1(a) shows that the exons appear to be
clustered in groups. At the very 5′ end of the gene the first
four exons are separated by a large intron from a tightly
grouped set of six exons. This latter set of exons is
separated by another large intron from another set of six
exons. Finally, another large intron separates this latter set
of exons from the remaining group of three exons. These
data highlight the unique genomic structure of murine
COMP. The GENBANK accession number for the murine
COMP sequence is AF318517.
When the mouse COMP sequence was compared to the
human genomic COMP sequence, a high degree of simi-
larity was evident. As shown in Fig. 1(b), the total DNA
sequence spanned by the genes is very similar, being
8.4 kb for the mouse and 8 kb for the human. Additionally,
the arrangement of the exons is very similar between the
two species, especially with regard to the internal sets of
exons. This similarity indicates a conservation in the exons
encoding the EGF-like repeats and the type 3 repeats. Of
the four areas of similarity in exon arrangement shown in
Fig. 1(b), the third group contains the exons that are most
frequently mutated in MED and PSACH. In fact most of the
mutations reside in exons 10 and 13. These data indicate
that the mouse and human genomic sequences show a
high degree of genomic conservation.
When the DNA sequence from the mouse genomic clone
was used to scan the recently available database for the
mouse genome sequencing project, two independent
genomic fragments were identified that contained the
COMP sequence (accession numbers AC073780 and
AC068650). While these sequences were not designated
as containing the COMP gene, in fact they align quite well
with our genomic clone, with a very small number of nucleo-
tide differences that may be due to sequence variation.
Given that the genomic structure of COMP appears to be
conserved well between mouse and man, it was important
to determine whether the sequences flanking the tran-
scribed region of the gene was also conserved, especially
with regard to the 5′ flanking region which appears to
contain the promoter. The mouse genomic clone we iso-
lated contains 483 bp of untranslated sequence and
appears to encompass the promoter22,23. The start site for
transcription of murine COMP, as indicated in Fig. 2, has
been previously determined by Issack et al. 2000, using a
5′RACE method22. From Fig. 2 it appears that there are a
number of clusters of DNA sequence with a high degree of
homology between the mouse and human promoters. The
regions of identity between the mouse and human
sequence are in bold and underlined in Fig. 2 and include
consensus binding sites for the transcription factors AP2,
AP4, Krox/Sp1/EGFR, HMG-box, ZF87/MAZ and the TATA-
binding protein. There also exist a number of DNA motifs
that are identical between the mouse and human pro-
moters that do not conform to any known transcription
factor binding site (indicated by the asterisks in Fig. 2).
Additionally, the consensus Sp1 and AP1 binding sites
in the mouse promoter (positions 32 and 70) are not
conserved in the human promoter.Fig. 4. The activity of the COMP repressor is not cell type specific.
The indicated promoter constructs (30 g each) were individually
transfected into the indicated cell lines: COS (a), U2OS (b), Saos2
(c) and Phoenix (d). The transfections were performed as
described in Fig. 3. Shown are the resulting levels of promoter
activity relative to the −453 construct, which was arbitrarily set at 1.
Each experiment was performed multiple times and the mean
values (±S.D.) are shown.IDENTIFICATION OF A TRANSCRIPTIONAL REPRESSOR REGION
WITHIN THE COMP PROMOTER
To begin expression studies on the COMP promoter, a
DNA fragment extending from −453 to +14 relative to thestart site of transcription was subcloned adjacent to
the luciferase reporter gene in the pGL3 basic vector.
Additionally, a number of 5′ deletions were also cloned into
this vector, as outlined in Fig. 3(a). transient transfections
were initiated in C3H10T1/2 mesenchymal fibroblasts and
in rat chondrosarcoma cells (RCS). At 48 h post-
transfection extracts were isolated and processed for luci-
ferase activity. As seen in Fig. 3(b) and 3(c), the −453 and
−356 constructs show a very low level of promoter activity,
in both the fibroblasts and RCS cells. Apparently, the
putative Sp1 and Ap-1 sites [Fig. 3(a)] do not contribute
much to promoter activity, since their deletion in the −356
construct does not affect transcription. Upon deletion of
sequence to −304 the activity increases substantially,
indicating the presence of a repressor element between
positions −356 and −304. Deletion from −304 to −251
results in a drop in activity indicating the presence of
activator binding in this region. Interestingly, deletion to
−180 leads to a very dramatic up-regulation in promoter
activity in both cell types. These results suggest the pres-
ence of an additional repressor located between −251 and
−180. Further deletion to −100 leads to a drop in promoter
activity, suggesting that the Ap-4 and Krox sites, as well as
the additional conserved sequences, are probably acting in
Osteoarthritis and Cartilage Vol. 10, No. 8 643Fig. 5. The COMP repressor sequence acts on a heterologous
promoter and enhancer to repress transcription. The region of the
COMP promoter extending from −452 to −180 containing the
repressor sequence was subcloned adjacent to the SV40 promoter
in two separate plasmids. One plasmid contained only the SV40
promoter linked to luciferase (SV40-Luc), while the second pro-
moter contained both the SV40 promoter linked to luciferase as
well as the SV40 enhancer (SV40Enhancer-Luc). Transfections
(30 g of plasmid) were performed in either C3H10T1/2 fibroblasts
or RCS cells. The transfections were performed as described in
Fig. 3. Shown are the resulting levels of promoter activity relative to
promoter constructs lacking the COMP repressor sequence which
was arbitrarily set at 1. Each experiment was performed multiple
times and the mean values (±S.D.) are shown.
Fig. 6. Sox9 is not able to transcriptionally transactivate the COMP
promoter. (a) Immunoblot. The pcDNA3-Sox9 expression plasmid
was transfected into RCS cells. At 48 h post-transfection, nuclear
extracts were generated, which were separated by SDS-PAGE.
The gel was blotted onto nitrocellulose and the blot incubated with
the M2 monclonal antibody specific for the FLAG tag at the amino
terminus of Sox9. The blot was developed using an alkaline
phosphatase secondary antibody. The developed blot is shown.
(b), (c) Promoter activity. The indicated promoter constructs (30 g
each) were individually transfected into RCS cells (b) or
C3H10T1/2 cells (c). The transfections were performed as
described in Fig. 3 in the presence or absence of a Sox9
expression plasmid. Shown are the resulting levels of promoter
activity relative to the −453 construct (in the absence of Sox9),
which was arbitrarily set at 1. Each experiment was performed
multiple times and the mean values (±S.D.) are shown.a positive fashion to enhance transcription. Finally, deletion
to −34 results in a further drop in transcription in the RCS
cells, while it leads to an increase in transcription in the
C3H10T1/2 cells. This would indicate that the AP-2 and
AP-4 sites near the TATA-box play a positive role in
enhancing transcription in the C3H10T1/2 cells. In total
these data indicate that two independently acting repressor
elements exist in the region between −356 and −304 and
between −251 and −180. Removal of both of these regions
leads to a 120-fold (C3H10T1/2) and a 28-fold (RCS cells)
enhancement of transcription.
To determine if the repressive activity of the region of the
COMP promoter spanning residues −453 to −180 was cell
type specific, transfections were also performed into two
osteosarcoma lines (Saos 2 and U2OS) and two trans-
formed epithelial lines (COS and Phoenix). As shown in
Fig. 4, the repressive activity of the COMP promoter is
evident in all four cell lines. Deletion of the repressor
sequence results in a significant enhancement of promoter
activity, from 35- to 800-fold, depending on the cell type.
These data indicate that this region of the COMP promoter
functions to repress transcription in a variety of cell typesand is not restricted to mesenchymal cells or cells of the
chondrocyte lineage.
To determine if these repressor sequences located
between −453 and −180 of the COMP promoter could act
on a heterologous promoter, the sequence was cloned into
a luciferase reporter vector containing either the SV40
644 F. Han et al.: The murine COMP promoter contains a potent transcriptional repressor regionpromoter or the SV40 promoter plus enhancer. In both
constructs the sequence was cloned just 5′ to the SV40
promoter. As seen in Fig. 5, while the repressor sequence
significantly down-regulates promoter activity in both
vectors, it has the greatest effect in the vector contain-
ing both the SV40 promoter and enhancer, diminishing
promoter activity from 10 fold (RCS cells) to 100 fold
(C3H10T1/2 cells). This would indicate that the repressor
sequence is more effective at modulating activity from
promoters containing additional regulatory enhancer
elements.
The region of the COMP promoter analysed here con-
tains a sequence that partially matches an HMG-box. This
sequence has the potential of binding Sox 9, an HMG-box
binding transcription factor that is known to transactivate
cartilage specific genes (e.g. collagen type II). To determine
if Sox 9 was able to transactivate the COMP promoter,
co-transfections were performed with the COMP promoter
constructs [as outlined in Fig. 3(a)] and a Sox9 expression
plasmid. Figure 6(a) shows the ectopic expression of Sox9
following transient transfection of the Sox9 expression
plasmid into the rat chondrosarcoma cells. In the
co-transfection experiments in RCS cells, Sox 9 had an
inhibitory effect on transcription from a majority of the
COMP promoter constructs, and appeared to have no
effect on the −453 deletion construct [Fig. 6(b)]. When the
transfections were performed in C3H10T1/2 cells, no sig-
nificant effect was seen by Sox 9. Since the −453 deletion
is not affected by Sox 9 in either cell line, it appears that
Sox 9 does not target this portion of the COMP promoter.Fig. 7. Schematic of the murine COMP promoter. The more proximal region of the COMP promoter is shown with positions of repressor as
well as activator elements. Also shown are the positions of potential binding sites for known transcription factors.Discussion
Here we have reported the isolation and characterization
the genomic clone of the murine COMP gene. Analysis of
the genomic sequence clearly shows that the murine and
human genomic sequences of COMP share a number of
significant similarities, in terms of the size of the gene and
the number and arrangement of exons, indicating a high
degree of structural conservation between murine and
human COMP. For example, COMP contains an array of
both EGF-like repeats and type 3 repeats that are consid-
ered essential structural and functional components of the
protein. This is highlighted by the fact that almost all of the
mutations that have been identified in patients with PSACH
or MED occur in the region encompassing these type 3
repeats. These mutations are probably generated through
a mechanism of expansion or contraction of trinucleotiderepeats15. Interestingly, the arrangement of the exons
encoding the EGF-like and type 3 repeats is highly
conserved between the human and mouse genes.
The conservation between the mouse and human
genomic sequences extends into the 5′ flanking area,
encompassing the promoter, where we find a number of
sequence motifs with a high level of homology. These
include consensus sites for binding of the AP-1, AP-2,
AP-4, Sp1, Krox/Sp1/EGF-R24, HMG-box and ZF87/MAZ25
transcription factors. The presence of these sites is consist-
ent with the complex makeup of promoters for a number of
extracellular matrix genes. While some of these sites
appear to play a role in activating transcription, such as the
AP-2 and AP-4 sites as well as the potential conserved
sequences flanking the 5′ most AP-4 site at position −138,
other sites do not appear to play a strong role in activating
transcription, such as the 5′-most Sp1 and Ap-1 sites,
and instead may play a more subtle role in controlling
transcription under certain conditions.
What was most interesting from the promoter analysis
presented here is the presence of two repressor elements
located between residues −356 and −304 and between
−251 and −180, as outlined in Fig. 7. These repressor
sequences significantly lowered the level of transcription
from the COMP promoter. In addition, when the entire
repressor region was cloned adjacent to the SV40 pro-
moter and enhancer, it significantly down-regulated tran-
scription, indicating that it functions against a heterologous
promoter. When these two repressor regions were ana-
lysed in more detail, it was found that they share two
overlapping sequences [A(A/G)CCAGAGTG] and [G(G/T)
GAGT]. These sequences do not correspond to any well-
defined transcription factor binding sites. In addition, these
sequences are also found in the human COMP promoter,
around position −324. Current efforts are underway to
determine if these elements within the murine promoter are
indeed the repressor sequences.
The fact that this region acts to repress transcription from
the COMP promoter in a variety of non-cartilage cell types
indicates that the proteins working through these sites are
likely to be broadly expressed and may function to down
regulate COMP transcription in non-cartilage tissues. The
identification of these proteins and their cognate binding
sites will be important if we are to understand how COMP
transcription is regulated.
Finally, the data presented here are consistent with
those presented recently by Issacks et al., 200022. They
showed that an apparent repressor element exists in this
Osteoarthritis and Cartilage Vol. 10, No. 8 645same region of the COMP promoter. Interestingly, a
chondrocyte specific enhancer distal to the promoter
appears to be able to overcome this repressor activity
leading to significant up-regulation of COMP transcription.
The nature of this cartilage specific COMP enhancer is not
yet known. However, it will be of interest to determine how
this enhancer accomplishes its function in the face of a
potent transcriptional repressor. This will give insight into
the mechanism of tissue specific regulation of COMP gene
transcription.Acknowledgments
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